CD47 Protein (CD47) (AA 19-139) (Fc Tag,AVI tag,Biotin)
-
- Antigène Voir toutes CD47 Protéines
- CD47
- Type de proteíne
- Recombinant
- Activité biologique
- Active
- Attributs du protein
- AA 19-139
-
Origine
- Humain
-
Source
- HEK-293 Cells
- Purification/Conjugué
- Cette CD47 protéine est marqué à la Fc Tag,AVI tag,Biotin.
- Marque
- MABSol®,PrecisionAvi
- Séquence
- AA 19-139
- Specificité
- Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
- Attributs du produit
- This protein carries a human IgG1 Fc fragment at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 42.2 kDa. The protein migrates as 50 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.
- Pureté
- >95 % as determined by SDS-PAGE.
- niveau d'endotoxine
- Less than 1.0 EU per μg by the LAL method.
- Top Product
- Discover our top product CD47 Protéine
-
-
- Commentaires
-
Ready-to-use AvitagTM biotinylated protein:
The product is exclusively produced using the AvitagTM technology. Briefly, a unique 15 amino acid peptide, the Avi tag, is introduced into the recombinant protein during expression vector construction. The single lysine residue in the Avi tag is enzymatically biotinylated by the E. Coli biotin ligase BirA.
This single-point enzymatic labeling technique brings many advantages for commonly used binding assays. The biotinylation happens on the lysine residue of Avi tag, and therefore does NOT interfere with the target protein's natural binding activities. In addition, when immobilized on an avidin-coated surface, the protein orientation is uniform because the position of the Avi tag in the protein is precisely controlled. - Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Buffer
- Tris with Glycine, Arginine and NaCl, pH 7.5
- Conseil sur la manipulation
- Please avoid repeated freeze-thaw cycles.
- Stock
- -20 °C
-
-
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy." dans: Journal for immunotherapy of cancer, Vol. 8, Issue 2, (2020) (PubMed).
: "Cancer immunotherapy targeting the CD47/SIRPα axis." dans: European journal of cancer (Oxford, England : 1990), Vol. 76, pp. 100-109, (2017) (PubMed).
: "
-
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy." dans: Journal for immunotherapy of cancer, Vol. 8, Issue 2, (2020) (PubMed).
-
- Antigène
- CD47
- Autre désignation
- CD47 (CD47 Produits)
- Synonymes
- IAP Protein, MER6 Protein, OA3 Protein, 9130415E20Rik Protein, AA407862 Protein, AI848868 Protein, AW108519 Protein, B430305P08Rik Protein, Itgp Protein, CD47/IAP Protein, alkaline phosphatase, intestinal Protein, CD47 molecule Protein, CD47 antigen (Rh-related antigen, integrin-associated signal transducer) Protein, Cd47 molecule Protein, ALPI Protein, CD47 Protein, Cd47 Protein
- Sujet
- Leukocyte surface antigen CD47 is also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP) and Protein MER6. CD47 contains 1 Ig-like V-type (immunoglobulin-like) domain. CD47 is very broadly distributed on normal adult tissues. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation.
- Poids moléculaire
- 42.2 kDa
- NCBI Accession
- NP_942088
-